ipharmacy

FDA Safety Alert

Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency

U.S. Food and Drug Administration
August 24, 2026
ID: http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential

FDA MedWatch Safety Alert

AUBURN, Ala. (August 21, 2026) – Vitruvias Therapeutics, Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent.

Content syndicated from the official FDA MedWatch Safety Alerts and Adverse Event Reporting Program.

View Official Announcement on FDA.gov